Fourteen major Midwest medical research institutions with their best and brightest technologies in one place!

CINCINNATI CHILDREN’S HOSPITAL
KANSAS STATE UNIVERSITY
MAO CLINIC
PURDUE UNIVERSITY
UNIVERSITY OF COLORADO
UNIVERSITY OF IOWA
UNIVERSITY OF KANSAS
UNIVERSITY OF KENTUCKY
UNIVERSITY OF MISSOURI
UNIVERSITY OF MISSOURI-KC
UNIVERSITY OF NEBRASKA
UNIVERSITY OF NOTRE DAME
UNIVERSITY OF OKLAHOMA
WARF

Sept. 30-Oct. 1, 2019 » Omaha

REGISTER AT: MWDRUGDEVELOPMENT.COM
TWO DAY CONFERENCE
Featuring about 50 of the best early- and mid-stage therapeutic technologies that Midwestern institutions have to offer.

Sept. 30-Oct. 1, 2019  ➞  Omaha

A glance at some of the planned presentations for 2019:

- Antibacterials for methicillin, vancomycin resistant bacteria
- Antibiotics to treat highly resistant enterococcus
- Antimicrobial peptides for therapeutics
- Antisense oligonucleotides to treat spinal muscular atrophy
- Autologous CD117+ progenitor cell therapy for allograft prolongation

- Combine nanoparticles, checkpoint blockade therapy
- Composite biodegradable formulation promotes bone regeneration in diabetics
- Enhance vaccine responses
- Family of small molecule drugs to treat diabetes complications
- Fast-acting, reversible neuromuscular blockers

- GGDPS inhibitors for the treatment of cancer
- Glucocorticoid prodrugs for the treatment of nephritis
- GM-CSF to treat Alzheimer’s disease
- GRP94-selective therapeutics to treat cancer, glaucoma
- Kappa opioid receptor antagonists to treat depression, anxiety

- Liposomal formulations of combinational antibiotics
- Low-molecular weight anti-PD-L1 peptide for cancer immunotherapy
- Matrix metalloproteinase inhibitors to treat diabetic foot ulcers

Startups
Nanoparticle drug delivery systems
● Novel Compounds to treat AML, MDS
● Novel crocetin compound prevents, treats pancreatic cancer

● Novel licofelone analogs for chronic inflammatory diseases, epithelial cancers
● Novel mithramycin derivatives for cancer chemotherapy
● Novel peptide antagonists for modulating GPCR pharmacology
● Peptide-based methods to treat neurological injury, disease
● Preventative therapy treats post-traumatic osteoarthritis

● Protease inhibitor drugs with improved PK, bioavailability
● Small molecule inhibitors of NAMPT
● Small molecule ligand for PSMA-targeted radioligand therapy
● Small molecule Rac inhibitor as new therapy
● Small molecule therapeutic for lupus

● Small molecule treatment targets lymphoblastic leukemia/lymphoma
● Treat macular degeneration with cell therapy
● Treat multiple myeloma and other solid cancers
● VSV cDNA libraries for cancer immuno/virotherapy

Startups

University of Kentucky
University of Kansas
University of Missouri
University of Notre Dame
University of Oklahoma
University of Wisconsin-Madison
MidWest Drug Development Conference

REGISTER AT: MWDRUGDEVELOPMENT.COM

Sept. 30-Oct. 1, 2019 » Omaha

$5.74 BILLION IN RESEARCH
2,313 NEW INVENTIONS
877 LICENSING AGREEMENTS
702 U.S. PATENTS
145 NEW PRODUCTS
108 STARTUPS FORMED
22 BLOCKBUSTERS

MEET NEW PARTNERS
UNEARTH HIDDEN GEMS